ACTRN12618000592246招募中不适用
A Randomised Multi-centre Placebo Controlled Trial of Fenofibrate for Treatment of Diabetic Macular Oedema with Economic Evaluation
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 392
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 25 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Male or Female patients >= 25 years at the time of consent.
- •2. Diagnosed with type 2 diabetes
- •3. Diagnosed with DME on SD-OCT.
排除标准
- •1. Current use of fenofibrate
- •2. Pregnancy, or intention to become pregnant within the trial period
- •3. Contraindication to fenofibrate use.
- •4. Other causes of macular oedema including epiretinal membrane, vitreomacular traction, retinal vein occlusion, AMD, cataract surgery in the last 6 months.
- •5. Previous treatment for DME in the prior 12 months including focal/grid laser, anti-VEGF injections, intravitreal triamcinolone injections.
- •6. Active retinal neovascularisation requiring pan retinal photocoagulation laser therapy.
研究者
相似试验
招募中
2 期
Dextran in Carotid Endarterectomy TrialCarotid Endarterectomy and ThromboembolismStroke - IschaemicACTRN12609000673246ational Stroke Research Institute and John Hunter Health1,412
进行中（未招募）
2 期
Epicutaneous Immunotherapy for Milk AllergyFood allergy (milk)Food allergy, milk allergy, anaphylaxisT781JPRN-jRCTs041200024Takase Takafumi40
进行中（未招募）
不适用
A Multicentre Randomised Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose (1,000 mg iron) in Improving Fatigue Symptoms in Iron-deficient Non-anaemic (IDNA) Women of Child Bearing AgeEUCTR2009-017737-21-ATVifor Pharma288
进行中（未招募）
不适用
A Multicentre Randomised Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose (1,000 mg iron) in Improving Fatigue Symptoms in Iron-deficient Non-anaemic (IDNA) Women of Child Bearing AgeEUCTR2009-017737-21-SEVifor Pharma288
进行中（未招募）
不适用
A Multicentre Randomised Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose (1,000 mg iron) in Improving Fatigue Symptoms in Iron-deficient Non-anaemic (IDNA) Women of Child Bearing AgeTreatment of iron deficient non anaemic women with ferric carboxymaltose.MedDRA version: 12.1Level: LLTClassification code 10022970Term: Iron deficiencyEUCTR2009-017737-21-DEVifor Pharma288